Pfizer Outlines Postacquisition Manufacturing Strategy
ePT--the Electronic Newsletter of Pharmaceutical Technology
Following its $68-billion acquisition of Wyeth, Pfizer is integrating its manufacturing and outsourcing activities (Podcast).
Following its $68-billion acquisition of Wyeth (Madison, NJ), Pfizer (New York) is integrating its manufacturing and outsourcing activities. In a joint podcast with its sister publication BioPharm International, Pharmaceutical Technology discusses Pfizer's plans for manufacturing integration with Tony Maddaluna, senior vice-president of strategy and supply-network transformation at Pfizer Global Manufacturing. The podcast is moderated by Laura Bush, editor-in-chief of BioPharm International.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
